Sample size for equivalence trials: A case study from a vaccine lot consistency trial

被引:5
作者
Gaiju, Jitendra [1 ]
Izu, Allen [2 ]
Allemona, Alessandra [3 ]
机构
[1] Amgen Inc, San Francisco, CA 94080 USA
[2] Novartis Vaccines & Diagnost Inc, Cambridge, MA USA
[3] Novartis Vaccines & Diagnost Inc, Siena, Italy
关键词
sample size; power; variance components; vaccine lot consistency; equivalence;
D O I
10.1002/sim.3273
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
For some trials, simple but subtle assumptions can have a profound impact on the size of the trail. A case in point is a vaccine lot consistency (or equivalence) trial. Standard sample size formulas used for lot consistency trials rely oil only one component of variation, namely, the variation in antibody titers within lots. The other component the variation in the means of titers between lots, is assumed to be equal to zero. In reality, some amount of variation between lots, however small, will be present even under the best manufacturing practices. Using data from a published lot consistency trial, we demonstrate that when the between-lot variation is only 0.5 per cent of the total variation, the increase in the sample size is nearly 300 per cent when compared with the size assuming that the lots are identical. The increase in the sample size is so pronounced that in order to maintain power one is led to consider a less stringent both components of variation is provided. We also due to correlated comparisons arising from tree pairs of lots as a function of the between-lot variance. Copyright (C) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:3743 / 3754
页数:12
相关论文
共 18 条
[11]   ESTIMATION OF REGRESSION-COEFFICIENTS WHEN SOME REGRESSORS ARE NOT ALWAYS OBSERVED [J].
ROBINS, JM ;
ROTNITZKY, A ;
ZHAO, LP .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1994, 89 (427) :846-866
[12]   A COMPARISON OF THE 2 ONE-SIDED TESTS PROCEDURE AND THE POWER APPROACH FOR ASSESSING THE EQUIVALENCE OF AVERAGE BIOAVAILABILITY [J].
SCHUIRMANN, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (06) :657-680
[13]   Bayesian design and analysis of active control clinical trials [J].
Simon, R .
BIOMETRICS, 1999, 55 (02) :484-487
[14]   Controlling the type 1 error rate in non-inferiority trials [J].
Snapinn, Steven ;
Jiang, Qi .
STATISTICS IN MEDICINE, 2008, 27 (03) :371-381
[15]   Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials [J].
Snapinn, Steven ;
Jiang, Qi .
STATISTICS IN MEDICINE, 2008, 27 (03) :382-391
[16]   DIABETES, OTHER RISK-FACTORS, AND 12-YR CARDIOVASCULAR MORTALITY FOR MEN SCREENED IN THE MULTIPLE RISK FACTOR INTERVENTION TRIAL [J].
STAMLER, J ;
VACCARO, O ;
NEATON, JD ;
WENTWORTH, D .
DIABETES CARE, 1993, 16 (02) :434-444
[17]  
Wiens B L, 1999, J Biopharm Stat, V9, P465, DOI 10.1081/BIP-100101188
[18]   Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children [J].
Zangwill, KM ;
Droge, J ;
Mendelman, P ;
Marcy, SM ;
Partridge, S ;
Chiu, CY ;
Jing, J ;
Chang, SJ ;
Cho, IS ;
Ward, JI .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (08) :740-746